nified protocol for transdiagnostic treatment of emotional disorders in adolescents
Early Phase 1
- Conditions
- Social phobia disorder.Social phobiasF40.1
- Registration Number
- IRCT20230608058424N1
- Lead Sponsor
- Shahed University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 5
Inclusion Criteria
Adolescent girl
Live in Tehran
With social anxiety disorder
Age 13-16 year
Informed consent
Exclusion Criteria
Non-participation in simultaneous treatment
Suicidal ideation or thought of murder
Drug and alcohol abuse
Psychosis in person or parents
Major educational failure
Psychiatric hospitalized in the last six months
Education less than 9 classes
Absence of participation in at least 3 modules of therapy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Social anxiety score in SPIN questionnaire. Timepoint: The beginning of module 1, the end of modules 4 and 8, and 1/5 month follow-up. Method of measurement: Spin questionnaire.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the transdiagnostic treatment protocol for social phobia (F40.1) in adolescents in IRCT20230608058424N1?
How does the unified protocol for emotional disorders in adolescents compare to standard CBT or SSRIs in treating social phobia (F40.1)?
Which biomarkers are used to predict treatment response in the transdiagnostic approach for social phobia (F40.1) in IRCT20230608058424N1?
What are the potential adverse events and management strategies for the early phase I transdiagnostic treatment of social phobia (F40.1) in adolescents?
Are there existing combination therapies or pharmacological agents targeting serotonin or GABA systems for adolescent emotional disorders similar to IRCT20230608058424N1?